Twist Bioscience Corporation (TWST) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Diagnostics & Research Branche. Der Hauptsitz des Unternehmens ist in South San Francisco, CA, United States. Der aktuelle CEO ist Emily Marine Leproust.
TWST hat IPO-Datum 2018-10-31, 923 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $3.52B.
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells synthetic DNA-based products using its proprietary DNA synthesis platform, which writes DNA directly onto silicon chips. The company offers a diverse portfolio including synthetic genes, sample preparation tools, antibody libraries for drug discovery, and DNA-based digital data storage solutions. Twist has established strategic collaborations with leading pharmaceutical and biotechnology firms such as Boehringer Ingelheim, Kyowa Kirin, and Centogene to advance sequencing tools and therapeutic antibody discovery. Founded in 2013 and headquartered in South San Francisco, California, the company serves the pharmaceutical, diagnostics, and data storage industries.
